FACBC Articles


  • Combined (18)F-Fluciclovine PET/MRI shows potential for detection and characterization of high-risk prostate cancer.

    The objective of this study is to investigate if quantitative imaging features derived from combined (18)F-Fluciclovine Positron Emission Tomograpy (PET) / multiparametric Magnetic Resonance Imaging (MRI) show potential for detection and characterization of primary prostate cancer.

    Published October 10, 2017
  • Imaging of Prostate Cancer Using Fluciclovine.

    Prostate cancer is the most common cancer and the second leading cause of cancer death in men in the United States. Despite high disease prevalence, diagnosis and surveillance of the disease with conventional imaging are limited typically because of indolent biology.

    Published March 15, 2017
  • Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET.

    Imaging of prostate cancer presents many challenges to the imaging community. There has been much progress in this space in large part due to MRI and PET radiopharmaceuticals. Though MRI has been focused on the evaluation of local disease and PET on the detection of metastatic disease, these two areas do converge and will be complementary especially with the growth of new PET/MRI technologies.

    Published October 22, 2015
  • Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.

    To compare the diagnostic performance of the synthetic amino acid analogue PET radiotracer anti-3-[(18)F]FACBC (fluciclovine) with that of CT in the detection of recurrent prostate carcinoma.

    This was a retrospective analysis of 53 bone scan-negative patients with suspected recurrent prostate carcinoma who underwent fluciclovine PET/CT and routine clinical CT within 90 days of each other.

    Published April 27, 2016
  • SNMMI 2016: Fluciclovine F18 (FACBC): An Amino Acid Tracer for the Staging of Recurrence Prostate Cancer

    San Diego, CA. USA (UroToday.com) – Coming off the recent FDA approval of Flucicovine F18 (FACBC), trade name Axumin®, it was with obvious excitement the CEO of Blue Earth Diagnostics discussed the research which lead to the recent news. Flucicovine is a synthetic amino acid based PET agent, which has been approved in men with suspected prostate cancer recurrence based on elevated PSA. 
    Published July 11, 2016
  • SNMMI 2016: Fluciclovine F18 PET-CT scanning in patients with high-risk primary prostate carcinoma

    San Diego, CA. USA (UroToday.com) – F-18 fluciclovine (FACBC) has been used as an investigational PET radiopharmaceutical to image patients with prostate cancer based on elevated amino acid transports in prostate cancers.  Its utility for disease staging has not been established for patients with high-risk primary prostate cancer. 
    Published July 11, 2016
  • Update on18F-fluciclovine PET for prostate cancer imaging.

    Positron emission tomography (PET) is a functional imaging method that can exploit various aspects of tumor biology to enable greater detection of prostate cancer than can be provided by morphologic imaging alone.

    Published March 13, 2018